Showing results (171-180 of 319) with videos related to

Sort By:
Pageof 32
Chemical & Pharmaceutical Bulletin|April 2, 2019
Molecular Mechanisms for Protection of Hepatocytes against Bile Salt CytotoxicityShin-Ya Morita, Yoshito Ikeda, Tokuji Tsuji, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 14, 2009
Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patientsKeiko Hosohata, Satohiro Masuda, Toshiya Katsura, et al.
Drug Metabolism and Pharmacokinetics|November 1, 2008
Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bileMasahiro Shimomura, Satohiro Masuda, Maki Goto, et al.
Clinical Pharmacology and Therapeutics|August 9, 2005
Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patientsMasahide Fukudo, Ikuko Yano, Satohiro Masuda, et al.
Clinical Pharmacology and Therapeutics|January 18, 2006
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patientsSatohiro Masuda, Maki Goto, Sachio Fukatsu, et al.
Pharmaceutical Research|March 10, 2009
MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patientsKeiko Hosohata, Satohiro Masuda, Atsushi Yonezawa, et al.
Pageof 32